Investment Rating - The report maintains a "Buy" rating for the company, with a target price set at 28.57 [1][6]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 2.67 to 3.34 billion yuan in 2025, representing a year-on-year growth of 30.0% to 62.5% [4]. - The "He Wa" platform, driven by AI strategy, is anticipated to create a second growth curve for the company, significantly enhancing job matching accuracy and order conversion efficiency [5]. - The company has successfully turned around its overseas business, contributing nearly 150 million yuan in profit in the first three quarters, marking it as a new profit growth point [5]. Financial Performance - The company forecasts net profits of 2.88 billion yuan, 3.42 billion yuan, and 4.0 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 40.23%, 18.6%, and 17.22% [6][7]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 1.46 yuan, 1.74 yuan, and 2.03 yuan respectively, with corresponding price-to-earnings (PE) ratios of 20X, 16X, and 14X [6][7]. - The company’s revenue is projected to grow from 11.79 billion yuan in 2024 to 21.46 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 19.64% [7]. Business Operations - The core flexible staffing business has shown steady growth, with over 50,900 outsourced personnel as of Q3, a year-on-year increase of 20.06%, and a 70.97% share of high-value technical positions [5]. - The company has optimized its mid-to-high-end recruitment business, maintaining revenue despite a 22% reduction in consultant numbers, resulting in a 15% increase in productivity [5].

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - AbbVie has submitted regulatory applications for its JAK inhibitor Rinvoq for the treatment of non-segmental vitiligo to both the FDA and EMA, based on positive results from the Phase 3 Viti-Up clinical study [5]. - The pharmaceutical sector showed a slight increase of +0.18% on February 5, 2025, outperforming the CSI 300 index by 0.78 percentage points, ranking 8th among 31 sub-industries [4]. - Among sub-industries, hospitals (+0.81%), offline pharmacies (+0.74%), and medical R&D outsourcing (+0.49%) performed well, while other bioproducts (-0.99%), vaccines (-0.44%), and pharmaceutical distribution (-0.25%) lagged behind [4]. Sub-industry Summary - Chemical pharmaceuticals: No rating [3] - Traditional Chinese medicine production: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other pharmaceutical industries: Neutral [3]

Investment Rating - The industry rating is optimistic, expecting overall returns to exceed the CSI 300 Index by more than 5% in the next six months [10]. Core Insights - The real estate sector is experiencing a positive market trend, with the Shanghai Composite Index and Shenzhen Composite Index rising by 1.29% and 2.35% respectively, while the Shenwan Real Estate Index increased by 1.90% [3]. - Beijing's first land auction of 2026 generated a total revenue of 8.562 billion yuan, with all plots sold at the base price [5]. - Fujian province is implementing various supportive measures to stabilize the real estate market, including housing subsidies for families with multiple children and other financial assistance [6]. Summary by Sections Market Performance - On February 3, 2026, the equity market saw most sectors rise, with the CSI 300 Index increasing by 1.18% and the CSI 500 by 3.11% [3]. Individual Stock Performance - The top five performing stocks in the real estate sector were Jingtou Development, Chengjian Development, Huaxia Happiness, Binjiang Group, and Rongfeng Holdings, with increases of 10.10%, 10.09%, 6.54%, 5.31%, and 4.98% respectively [4]. Industry News - The first land auction in Beijing for 2026 concluded with a total of 8.562 billion yuan, with notable purchases by Shougang Real Estate and China Iron and Steel Group [5]. - Fujian province has announced several measures to promote stability in the real estate market, including the implementation of housing subsidies and support for different levels of talent [6]. Company Announcements - Poly Development announced a bond buyback amounting to 940 million yuan, with a buyback period from January 26 to January 30, 2026 [8]. - Beijing Capital Development announced plans to apply for a revolving loan limit of 6 billion yuan from its controlling shareholder [8].

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [3][40]. Core Insights - The report highlights that the banking sector's performance is entering a recovery phase, with a focus on the stability of interest margins and the potential for improved asset quality as the economy recovers [7]. - The report emphasizes the importance of strong capital positions and reliable dividend payouts for investment selection, recommending specific banks based on their financial health and market position [7]. Summary by Sections Market Review - The Shanghai Composite Index and CSI 300 Index experienced changes of -0.44% and +0.08% respectively, while the banking sector index rose by 0.86%, outperforming the CSI 300 by 0.78 percentage points [10][11]. - Notable performances within the banking sector included increases in share prices for major state-owned banks such as Bank of China (+1.90%) and Agricultural Bank of China (+0.81%) [13][14]. Data Tracking - As of January 30, 2026, the banking sector's price-to-book (PB) ratio stands at 0.65, indicating a valuation at the 70.10 percentile over the past five years [6][19]. - The median dividend yield for individual stocks in the sector is 4.54%, which is 2.73 percentage points higher than the yield on 10-year government bonds [6][19]. Industry Dynamics - The Federal Reserve has decided to maintain interest rates between 3.5% and 3.75%, reflecting a balanced approach to managing inflation and employment concerns [33][35]. - The China Banking Association has introduced guidelines for the collection of personal consumption loans, aiming to standardize practices and promote healthy industry development [37][39].

Investment Rating - The report does not explicitly provide an investment rating for the industry [43]. Core Insights - The total number of ETFs listed in mainland China is 1,419, with a total scale of 5.46 trillion yuan. Among these, stock ETFs account for the largest share, both in number (1,111) and scale (3.23 trillion yuan) [2][7]. - The A-share market indices showed varied performance, with the Shanghai Composite Index closing at 4,117.95, reflecting a decline of 0.44%. Notably, the petrochemical, communication, and coal sectors experienced significant gains, while military, power equipment, and automotive sectors faced substantial declines [11][12]. - The wide-based ETFs experienced a net outflow of 3890.81 billion yuan this week, with the top three inflows being A500 ETF (+11.23 billion yuan), Double Innovation Leader ETF (+9.27 billion yuan), and Shanghai Index ETF (+5.42 billion yuan). Conversely, the top three outflows were from the CSI 300 ETF by E Fund (-747.27 billion yuan), CSI 300 ETF by Huatai-PB (-742.00 billion yuan), and CSI 300 ETF by Huaxia (-547.13 billion yuan) [30][31]. - The industry crowding degree monitoring indicated that sectors such as non-ferrous metals, oil and petrochemicals, and agriculture are currently crowded, while automotive, home appliances, and pharmaceuticals have lower crowding levels, suggesting potential investment opportunities [35]. Summary by Sections ETF Market Overview - As of January 30, 2026, the total number of ETFs in mainland China is 1,419, with a total scale of 5.46 trillion yuan. Stock ETFs dominate both in quantity (1,111) and scale (3.23 trillion yuan), representing 78.29% and 59.11% of the total respectively [2][7][9]. Domestic and International Equity Market Index Performance - The A-share market indices showed mixed results, with the Shanghai Composite Index down 0.44%. The petrochemical sector saw a rise of 7.95%, while the military sector dropped by 7.69% [11][12][19]. - In the Hong Kong market, the Hang Seng Index rose by 2.38%, while the Hang Seng Technology Index fell by 1.38% [20][21]. Stock ETF Fund Flows - The wide-based ETFs saw a net outflow of 3890.81 billion yuan, with significant inflows into A500 ETF and Double Innovation Leader ETF, while the CSI 300 ETFs faced the largest outflows [30][31][34]. Industry Crowding Degree Monitoring - The monitoring model indicates that sectors like non-ferrous metals and oil and petrochemicals are crowded, while automotive and pharmaceuticals are less crowded, suggesting areas for potential investment focus [35][36]. ETF Product Attention Signals - The report highlights potential arbitrage opportunities in specific ETFs, including a focus on gold and non-ferrous metal ETFs, while cautioning about potential pullback risks [41][42].

2026 年 02 月 02 日 行业日报 中性/维持 房地产 房地产 太平洋房地产日报（20260202）：西安 4.6 亿元成交 5 宗地块 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/5 25/4/17 25/6/27 25/9/6 25/11/16 26/1/26 子行业评级 | 和运营 | | | --- | --- | | 房 地 产 开 发 房地产服务 | 无评级 无评级 | 推荐公司及评级 相关研究报告 <<太平洋房地产日报（20260127）：宁 波挂牌 4 宗地块>>--2026-01-28 <<太平洋房地产日报（20260126）：天 津调整公积金贷款政策>>--2026- 01-27 <<太平洋房地产日报（20260123）：湖 南将推城市更新三年行动>>--2026- 01-24 房地产板块个股涨幅较大的前五名为阳光股份、荣丰控股、海南 高 速 、 中 天 服 务 、 亚 通 股 份 ， 涨 幅 分 别 为 5.14%/5.00%/3.77%/2.80%/1.31%； 个股跌幅较大的为皇庭 B、皇庭国际、南山控股、财信发展、三湘 印象，跌幅分别为-10.3 ...

大类资产与基金周报（20260126-20260130）—— [Table_Title] [Table_Message]2026-02-01 金融工程周报 黄金冲高回落，商品基金涨幅 4.75% [Table_Author] 证券分析师：刘晓锋 电话：13401163428 E-MAIL：liuxf@tpyzq.com 执业资格证书编码：S1190522090001 证券分析师：孙弋轩 电话：18910596766 E-MAIL：sunyixuan@tpyzq.com 执业资格证书编码：S1190525080001 内容摘要 太 平 洋 证 券 股 份 有 限 公 司 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 [Table_Summary] . 金 融 工 程 周 报 ◼ 大类资产市场概况：1）权益：本周 A 股市场中上证指数收盘 4117.95，涨跌幅-0.44%， 深证成指、中小板指数、创业板指、上证 50、沪深 300、中证 500、中证 1000、中证 2000、 北证 50 涨跌幅分别为-1.62%、-3.78%、-0.09%、1.13%、0.08%、-2.5 ...

2026 年 01 月 31 日 公司点评 增持/维持 中谷物流(603565) 目标价: 昨收盘:10.23 中谷物流，2025Q3 点评，利润稳健增长，运力继续扩张 分红政策，公司 24 年度派发现金股息约 16.59 亿人民币，约占当年 度净利润比例的 90.4%。年度内 1 次分红，每股约 0.79 元（含税）;若 以 24 年报披露日 A 股的股价计算，1 次分红累计股息率约 8.5%。25 年 中期已派发股息约 9.03 亿。 ■ 点评 ◼ 走势比较 (10%) 2% 14% 26% 38% 50% 25/2/5 25/4/17 25/6/27 25/9/6 25/11/16 26/1/26 中谷物流 沪深300 ◼ 股票数据 总股本/流通(亿股) 21/21 总市值/流通(亿元) 214.84/214.84 12 个月内最高/最低价 (元) 11.69/8.61 证券分析师：程志峰 电话：010-88321701 E-MAIL：chengzf@tpyzq.com 分析师登记编号：S1190513090001 ■ 事件 26 年初，中谷物流披露造船计划。回顾 25 年前三个季度，累计实 现营业总收 ...

Investment Rating - The industry is rated positively, with expectations for overall returns exceeding the CSI 300 index by more than 5% in the next six months [36]. Core Viewpoints - The report anticipates a comprehensive recovery in both domestic and international demand for construction machinery in 2025, maintaining a positive outlook on industry demand [10][21]. - Data from the Construction Machinery Industry Association indicates strong sales performance across various machinery categories in December, with notable year-on-year growth in excavators (10.9%), loaders (17.6%), and cranes (39.1%) domestically, and significant export increases for excavators (26.9%) and loaders (41.5%) [10][11]. - For the full year of 2025, domestic sales are projected to reach 118,518 excavators (up 17.9%) and 66,330 loaders (up 22.1%), while exports are expected to total 116,739 excavators (up 16.1%) and 61,737 loaders (up 14.6%) [10][11]. - The report highlights that favorable policies in real estate and infrastructure, along with the machinery replacement cycle, are expected to drive demand improvements [10][11]. - The "Belt and Road" initiative is anticipated to enhance overseas market opportunities for domestic manufacturers, particularly in mining machinery, as global mining capital expenditures rise [10][11]. Summary by Sections Industry Opinion and Investment Suggestions - The report emphasizes a positive outlook for the construction machinery sector, predicting a recovery in demand [10][21]. Key Company Announcements - XCMG is involved in the construction of the world's largest football stadium, showcasing its equipment's capabilities [12]. - Zoomlion has signed procurement agreements worth 180 million yuan with Latin American clients, reflecting its international market trust [12]. Market Performance Review - During the period from January 26 to January 30, the CSI 300 index rose by 0.1%, while the machinery sector declined by 4.2%, ranking 25th among all primary industries [30].